- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06208514
Brief Pain Exposure Therapy for Fibromyalgia (BPET) Study (BPET)
Brief Pain Exposure Therapy for Fibromyalgia - A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Beth Banner
- Phone Number: 734-998-5837
- Email: eledward@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Principal Investigator:
- John Sturgeon, PhD
-
Contact:
- Beth Banner
- Phone Number: 734-998-5837
- Email: eledward@med.umich.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Physician diagnosis of fibromyalgia (FM)
- 2016 American College of Rheumatology (ACR) Criteria for FM: Widespread pain index score is ≥ 7 and symptom severity scale score is ≥ 5, or widespread pain index score is 4 to 6 and symptom severity score is ≥ 9
- Able to read, write and speak English
- Internet access and audio-visual conferencing capability (e.g., Zoom meetings by phone or computer) in the home
Exclusion Criteria:
- Indication of a co-occurring (non-fibromyalgia) cause of chronic pain (e.g., inflammatory arthritis, autoimmune disorders, spinal cord injury, cancer)
- Currently receiving cognitive-behavioral therapy or other psychological therapies for pain
- Open litigation regarding chronic pain in the past 1 year, as assessed in preliminary study screening.
- Inability to provide informed consent and complete study procedures (e.g., indications of suspected major cognitive impairment via observations of study staff during consenting) that would preclude comprehension or participation in study protocols.
- Pregnant or breastfeeding
- Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brief pain exposure therapy (BPET)
|
Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol, and 7 for days post-treatment. Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain intensity based on the Numeric Pain Rating Scale between day 1 (T1) and day 60 (T5)
Time Frame: Day 1, Day 60
|
This is a one item scale that participants answer worst pain experienced from no pain (0) to worst pain imaginable (10).
|
Day 1, Day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Tampa Scale of Kinesiophobia (TSK) day 1 (T1) to day 60 (T5)
Time Frame: Day 1, Day 60
|
This is a 17-item survey that participants answer strongly disagree (1) to strongly agree (4). Total scores are between 17-68 with a higher value indicating higher kinesiophobia. |
Day 1, Day 60
|
Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference day 1 (T1) to day 60 (T5)
Time Frame: Day 1, Day 60
|
Four questions are included in the PROMIS for pain interference.
Participants will answer from not at all (1) to very much (5).
Scores range from 4-20 with a higher score indicating more interference.
|
Day 1, Day 60
|
Change in pain intensity based on the Numeric Pain Rating Scale from day 1 (T1) to day 210 (T8)
Time Frame: Day 1, Day 210
|
This is a one item scale that participants answer worst pain experienced from no pain (0) to worst pain imaginable (10).
|
Day 1, Day 210
|
Change in TSK from day 1 (T1) to day 210 (T8)
Time Frame: Day 1, Day 210
|
This is a 17-item survey that participants answer strongly disagree (1) to strongly agree (4). Total scores are between 17-68 with a higher value indicating higher kinesiophobia. |
Day 1, Day 210
|
Change in PROMIS Pain Interference from day 1 (T1) to day 210 (T8)
Time Frame: Day 1, Day 210
|
Four questions are included in the PROMIS for pain interference.
Participants will answer from not at all (1) to very much (5).
Scores range from 4-20 with a higher score indicating more interference.
|
Day 1, Day 210
|
Acceptability of intervention based on Mean scores on the Treatment Acceptability and Adherence Scale (TAAS)
Time Frame: Day 29
|
This is a 10-item survey that participant will complete after final intervention.
Questions are answered from strongly disagree (1), neither agree or disagree (4), to agree (7).
Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention).
|
Day 29
|
Feasibility based on the number of sessions attended
Time Frame: Day 29
|
Higher number of sessions attended shows higher level of feasibility.
|
Day 29
|
Feasibility based on the number of in-session and between-session practices completed
Time Frame: Day 29
|
Higher number of sessions and between-sessions completed shows higher level of feasibility.
|
Day 29
|
Feasibility based on open-ended feedback at the completion of the intervention
Time Frame: Day 29
|
Participants will complete the open-ended feedback form that has 4 questions regarding the intervention and will be summarized.
|
Day 29
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John Sturgeon, PhD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00238637
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Brief pain exposure therapy (BPET)
-
The University of Texas at Arlington59th Medical Wing; The University of Texas Health Science Center at San Antonio and other collaboratorsCompletedChronic Pain | Post-traumatic Stress DisorderUnited States
-
Baylor Research InstituteMedical College of Wisconsin; Froedtert HospitalNot yet recruitingPTSD | Posttraumatic Stress Disorder | Traumatic Injury
-
Baylor Research InstituteNational Institute on Disability, Independent Living, and Rehabilitation...RecruitingPTSD | Spinal Cord Injuries | Post-Traumatic Stress DisorderUnited States
-
University of UtahDuke UniversityRecruitingLow Back Pain | Chronic PainUnited States
-
St. Olavs HospitalNorwegian University of Science and Technology; The Research Council of Norway and other collaboratorsRecruitingSexual Dysfunctions, Psychological | Sleep Disturbance | Post Traumatic Stress Disorder | Depression, Anxiety | Activity, Motor | Pelvic Pain Syndrome | Rape Sexual Assault | Pelvic Floor Myalgia | Cortisol DeficiencyNorway
-
Academisch Ziekenhuis MaastrichtRecruitingSmall Fiber NeuropathyNetherlands
-
Laura E SimonsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedMusculoskeletal Pain | Chronic Pain, Widespread | Pediatric PainUnited States
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedMarijuana Abuse | Chronic Post-Traumatic Stress DisorderUnited States
-
Karolinska InstitutetColumbia UniversityActive, not recruiting
-
Teesside UniversitySouth Tees Hospitals NHS Foundation Trust; North Tees and Hartlepool NHS Foundation...CompletedThe Relationship Between Pain, Balance and Gait in People With Chronic Obstructive Pulmonary DiseasePain | Chronic Obstructive Pulmonary Disease | Balance Impairment | Gait ImpairmentUnited Kingdom